Welcome to our dedicated page for Cognition Therapeutics news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on Cognition Therapeutics stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company based in Pittsburgh, Pennsylvania. Established in 2007, the company is dedicated to discovering and developing small-molecule therapeutics aimed at treating age-related degenerative diseases and disorders of the central nervous system and retina.
At the heart of Cognition Therapeutics' innovation is its proprietary biology and chemistry platforms, which are utilized to identify novel drug targets and create disease-modifying therapies. The company's flagship product candidate, CT1812, is an orally administered small-molecule antagonist designed to breach the blood-brain barrier. CT1812 binds selectively to the S2R complex, potentially offering a unique therapeutic approach for patients.
Current Projects and Achievements:
- CT1812 is currently being evaluated in Phase 2 clinical trials for conditions such as Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD).
- Recent 2023 milestones include completing enrollment for the SHINE Study in mild-to-moderate Alzheimer's disease and initiating new clinical studies for early Alzheimer's and dry AMD.
- The SHIMMER study for mild-to-moderate DLB has also reached its target enrollment, with top-line results anticipated in the latter half of 2024.
The company has made significant strides in advancing its clinical programs. In 2023, the FDA approved the first disease-modifying biologics for Alzheimer’s disease, which has rejuvenated research and investment in this critical area. Cognition Therapeutics is leveraging this momentum in its ongoing research and clinical trials.
Financial Overview:
For the year ending December 31, 2023, Cognition Therapeutics reported cash and cash equivalents of approximately $29.9 million. Additional capital from a March 2024 offering has bolstered their financial position, providing the company with sufficient funds to support operations and capital expenditures through May 2025.
Research and development expenses for 2023 were $37.2 million, an increase from $30.3 million in 2022, reflecting higher costs associated with Phase 2 trials and personnel. General and administrative expenses remained relatively stable at $13.5 million.
The company continues to foster collaborations and partnerships to advance its scientific goals. Notably, the SHIMMER study is supported by a significant grant from the National Institute on Aging (NIA), totaling approximately $30 million.
For ongoing updates and detailed information about Cognition Therapeutics, visit their website at cogrx.com.
Cognition Therapeutics announced that the FDA has cleared its IND application for CT1812, aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). The Phase 2 MAGNIFY trial is set to commence in 2023, enrolling about 246 participants diagnosed with dry AMD and measurable GA. CT1812 is designed to protect retinal pigment epithelium (RPE) cells from damage, potentially slowing vision loss in patients. This trial expands the company's pipeline, highlighting its ability to address challenging diseases.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that its president and CEO, Lisa Ricciardi, will present at the Oppenheimer & Co Healthcare Conference occurring virtually from March 13-15, 2023. Ricciardi's presentation is scheduled for March 15, 2023, at 10:00 a.m. ET, where she will discuss the company's pipeline progress, recent achievements, and future milestones. Interested investors can access the live webcast and subsequent archived replay via the company’s investor site. Cognition Therapeutics focuses on developing therapeutics targeting age-related degenerative disorders, particularly through its lead candidate CT1812 aimed at treating Alzheimer’s disease and other related conditions.
Cognition Therapeutics (CGTX) has received FDA clearance to commence its 540-patient Phase 2 START study of CT1812 for early Alzheimer's disease. This innovative oral small molecule aims to block toxic beta amyloid effects on neurons. The study will be conducted at 50-60 North American sites and is backed by an $81 million NIH grant over five years. Initial results of CT1812 have been encouraging, and further investigation is expected to enhance treatment options for Alzheimer's. The trial will evaluate CT1812's efficacy and safety over 18 months against placebo, utilizing established cognitive assessment tools.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has launched its third podcast episode focused on Lewy body dementia, featuring caregivers who share their experiences and insights. The podcast, moderated by CEO Lisa Ricciardi, highlights key symptoms, preparation for doctor visits, and the challenges faced by caregivers. Lewy body dementias, affecting approximately 1.4 million Americans, include Parkinson’s disease dementia and dementia with Lewy bodies, sharing symptoms such as cognitive impairment and visual hallucinations. The company is conducting a Phase 2 SHIMMER trial for its candidate CT1812, with support from a $30M NIH grant.
Cognition Therapeutics (Nasdaq: CGTX) has completed enrollment for its Phase 2 SEQUEL study (COG0202) involving 16 adults with mild-to-moderate Alzheimer’s disease. This randomized, double-blind study aims to investigate the effects of CT1812 using quantitative electroencephalogram (qEEG) to measure changes in theta wave activity, which is linked to memory and information processing. Topline results are expected in mid-2023. The study is supported by a $5.3 million grant from the National Institute of Aging. CT1812 targets sigma-2 receptors to disrupt Aβ oligomers, potentially offering a novel approach to treat Alzheimer's disease.
Cognition Therapeutics (CGTX) recently released its second "Conversations" video podcast featuring experts discussing clinical data from the 2022 CTAD conference. The episode, moderated by Anthony Caggiano, M.D., focuses on insights from the lecanemab CLARITY study, emphasizing the importance of targeting amyloid oligomers for Alzheimer’s treatment. Cognition is advancing its lead candidate CT1812, targeting Alzheimer’s and related disorders, highlighting the necessity of innovative therapeutic approaches in neurodegenerative disease management.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced participation in the 6th Annual Sachs Neuroscience Forum, Biotech Showcase, and BIO Partnering at JPM, taking place alongside the J.P. Morgan Annual Healthcare Conference 2023.
The events will feature panel discussions and corporate presentations on Alzheimer's and cognitive disorders, scheduled for January 8-9, 2023, in San Francisco, CA. The Cognition management team will meet with investors and pharmaceutical companies to discuss corporate achievements and clinical development strategies.
Cognition Therapeutics announced the expansion of its Phase 2 SHINE clinical trial for CT1812, an experimental Alzheimer's treatment, to include sites in Spain, the Netherlands, and the Czech Republic, in addition to the USA. The trial aims to enroll 144 participants and investigates CT1812's ability to prevent synaptotoxic effects caused by oligomers. Initial trials indicate potential cognition improvements and brain volume preservation. The study receives approximately $30 million in grant funding from the National Institutes on Aging.
Cognition Therapeutics (Nasdaq: CGTX) announced significant advancements regarding its Phase 2 trial for CT1812, targeting geographic atrophy due to dry age-related macular degeneration (dry AMD). With dry AMD affecting 10 million people in the U.S., the company emphasizes the need for effective treatments. CT1812, an oral sigma-2 receptor modulator, has shown promise in preclinical studies, demonstrating potential to rescue retinal pigment epithelial (RPE) functions impaired by oxidative stress. Cognition is in discussions with the FDA to initiate trials involving over 200 participants.
Cognition Therapeutics has announced the activation of up to 30 sites across the USA for its ongoing SHIMMER clinical trial evaluating CT1812, a novel treatment for dementia with Lewy bodies (DLB). This Phase 2 study aims to assess the safety and efficacy of CT1812, enrolling around 120 adults over six months. DLB currently lacks approved treatments, affecting approximately 1.4 million people in the U.S. The trial is supported by a $30 million grant from the National Institute on Aging and aims to provide crucial insights into cognitive and physical activity changes in DLB patients.
FAQ
What is the current stock price of Cognition Therapeutics (CGTX)?
What is the market cap of Cognition Therapeutics (CGTX)?
What does Cognition Therapeutics, Inc. specialize in?
What is CT1812?
What recent achievements has Cognition Therapeutics made?
How is Cognition Therapeutics funded?
What are the company's main areas of research?
Where is Cognition Therapeutics located?
What are the financial highlights for Cognition Therapeutics in 2023?
How does CT1812 work?
What are some key milestones expected in 2024?
How can I stay updated on Cognition Therapeutics’ progress?
